Pheon Therapeutics

Pheon Therapeutics is an Antibody-Drug Conjugate (ADC) specialist developing next-generation ADCs for hard-to-treat cancers. Their lead program targets a novel, highly-overexpressed target in solid tumors, demonstrating an unprecedented preclinical therapeutic index. The company aims to rapidly advance its ADC pipeline through clinical proof of concept.

Funding Round: Series B

Funding Amount: $120M

Date: 21-May-2024

Investors: TCGX, BVF Partners, Lightspeed Venture Partners, Perceptive Advisors, Atlas Venture, Brandon Capital, Forbion, Research Corporation Technologies

Markets: Biotechnology, Oncology, Pharmaceuticals, Life Science, Medical, Therapeutics

HQ: Harpenden, Hertfordshire, United Kingdom

Founded: 2015

Website: https://www.pheontx.com/

LinkedIn: https://www.linkedin.com/company/pheon-therapeutics

Twitter: https://twitter.com/pheontx

Instagram:

Facebook:

Crunchbase: https://www.crunchbase.com/organization/pheon-therapeutics

Pitchbook: https://pitchbook.com/profiles/company/149081-05